News
Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly’s weight-loss drug Zepbound and its ...
Eli Lilly said on Wednesday it had sued four compounders for selling unapproved products containing tirzepatide, after a U.S.
The stock fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant ...
Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...
Pharmaceutical giant Eli Lilly alleges the companies are selling off-brand versions of its best-selling diabetes and ...
Eli Lilly announced the results of a clinical trial for its new pill, which the company said causes nearly 8% weight loss at ...
People diagnosed with type 2 diabetes might benefit soon from Eli Lilly's new orforglipron weight loss drug following its ...
Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...
Rather counterintuitively, following some promising news about a pipeline drug, one analyst tracking Eli Lilly (NYSE: LLY) ...
Given the potential opportunities in the sector, should investors buy Eli Lilly stock? Here's where the company and its stock ...
A daily pill from drugmaker Eli Lilly has shown safety results comparable to the leading injectable GLP-1 drugs Mounjaro and ...
Eli Lilly escalates its crackdown on unauthorized tirzepatide copies, filing lawsuits against four compounders accused of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results